Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-19
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [31] Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2-metastatic breast cancer receiving palbociclib
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    CANCER RESEARCH, 2018, 78 (04)
  • [32] Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in Real-World Setting in Taiwan
    Novick, Diego
    Rajan, Narayan
    Wei, Alice
    Cheng, Rebecca
    Colman, Sam
    Szende, Agota
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 98 - 104
  • [33] Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea
    Novick, Diego
    Lee, Sae Young
    Koo, Dong Hyun
    Szende, Agota
    Colman, Sam
    JOURNAL OF DRUG ASSESSMENT, 2022, 11 (01) : 12 - 19
  • [34] A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2-metastatic breast cancer
    Li, Yi
    Li, Wei
    Gong, Chengcheng
    Zheng, Yabin
    Ouyang, Quchang
    Xie, Ning
    Qu, Qing
    Ge, Rui
    Wang, Biyun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [35] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
  • [36] Treatment patterns for young women with HR+/HER2-metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
    Burstein, Harold J.
    Mayer, Erica L.
    DeMichele, Angela
    Harnett, James
    Mardekian, Jack
    McRoy, Lynn
    Bartlett, Cynthia Huang
    Koehler, Maria
    Rimawi, Mothaffar Fahed
    CANCER RESEARCH, 2018, 78 (04)
  • [37] Physician experiences and preferences in the treatment of HR+/HER2-metastatic breast cancer in the United States: aphysician survey
    Lin, Peggy L.
    Hao, Yanni
    Xie, Jipan
    Li, Nanxin
    Zhong, Yichen
    Zhou, Zhou
    Signorovitch, James E.
    Wu, Eric Q.
    CANCER MEDICINE, 2016, 5 (02): : 209 - 220
  • [38] Patient Preferences for HR+/HER2-Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment
    Arpino, Grazia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Lambertini, Matteo
    Igidbashian, Sarah
    Bellini, Martina
    Giuntoli, Serena
    Guillaume, Xavier
    Behillil, Julie
    Graziani-Taugeron, Claire
    CANCER RESEARCH, 2024, 84 (09)
  • [39] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR +, HER2-metastatic breast cancer patients in Japan
    Nozawa, K.
    Terada, M.
    Onishi, M.
    Ozaki, Y.
    Takano, T.
    Fakhouri, W.
    Novick, D.
    Haro, J. M.
    Faris, L. H.
    Kawaguchi, T.
    Tanizawa, Y.
    Tsurutani, Junji
    BREAST CANCER, 2023, 30 (04) : 657 - 665
  • [40] HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY
    Collin, S.
    Tse, J.
    Shaikh, N. F.
    Near, A.
    Hamilton, E.
    Brufsky, A.
    Gradishar, W.
    Mehta, S.
    Long, G. H.
    Toms, N.
    VALUE IN HEALTH, 2024, 27 (06) : S134 - S134
12345